Skip to main content

Immunocore Holdings plc

IMCR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001671927

No open-market purchases or sales by Immunocore Holdings plc insiders were filed in the last 90 days; 135 institutions reported holding it in 13F filings for Q2 2026, worth $1.65B in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Immunocore Holdings plc changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of IMCR: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders4145+4
Shares14.1M14.4M+272.5K (+1.9%)
Value$597.8M$561.1M−$36.7M (−6.1%)

New holders (13)

Institutions that held Immunocore Holdings plc at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to IMCR in Q2 2021
InstitutionSharesValue% of portfolio
Rhenman & Partners Asset Management AB90,000$3.52M0.24%
Point72 Asset Management, L.P.72,900$2.85M0.01%
Alps Advisors Inc57,273$2.24M0.02%
Legal & General Group Plc19,091$725.0K0.00%
J. Goldman & Co LP16,685$652.0K0.04%
Bank of New York Mellon Corp12,896$504.0K0.00%
Boothbay Fund Management, LLC6,056$236.0K0.01%
Geode Capital Management, LLC5,997$234.0K0.00%
Virtus ETF Advisers LLC5,634$220.0K0.09%
Zurcher Kantonalbank (Zurich Cantonalbank)3,864$151.0K0.00%
Leonteq Securities AG1,000$39.0K0.00%
State of Wyoming212$8.00K0.01%
Point72 Hong Kong Ltd3$00.00%

Sold out (9)

Institutions that held Immunocore Holdings plc at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of IMCR in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Invesco Ltd.150,658$6.41M
Sphera Funds Management Ltd.36,000$1.53M
Alyeska Investment Group, L.P.35,000$1.49M
Pinz Capital Management, LP18,700$796.0K
Caas Capital Management LP15,000$639.0K
Anson Funds Management LP10,000$426.0K
Zimmer Partners, LP10,000$426.0K
Laurion Capital Management LP5,000$213.0K
Rokos Capital Management LLP500$21.0K